Paris, November 5 (ots/PRNewswire) – Sanofi-aventis announced today that it is a partner in a new multidisciplinary atrial fibrillation research consortium, the “European Network for Translational research in Atrial Fibrillation” (EUTRAF), which has been awarded a EUR12 million grant to engage in atrial fibrillation (AF) research. The European consortium is commencing a five-year research project [...]
Tag Archive > Camm
Survey Reveals Many are Ignoring Basic Measures to Check for no.1 Heart Killer Disorder in Europe
STRATFORD- UPON-AVON, England, June 7, 2010 (ots/PRNewswire) – – On World Heart Rhythm Week, Arrhythmia Alliance Launches ‘Know Your Pulse’ Campaign to Raise Awareness of the Importance of Pulse Checking to Keep Cardiac Conditions Under Control Arrhythmia Alliance, the Heart Rhythm Charity, announced today the results of a survey conducted in Europe that showed a [...]
First Global Atrial Fibrillation Registry, RecordAF, Shows Rhythm-Control Strategy With Current Therapies Achieves Improved Disease Control but not Clinical Outcomes
Orlando, Florida, November 15 (ots/PRNewswire) – Results from the RecordAF registry (REgistry on Cardiac rhythm disORDers assessing the control of Atrial Fibrillation), presented today at the Scientific Sessions of the American Heart Association, show that in recently diagnosed and actively treated patients with atrial fibrillation (AF), a rhythm-control strategy provides better short term control of [...]
Edoxaban – ein oraler Gerinnungshemmer in der Entwicklung / Phase-III-Studie über eine neue Behandlungsmöglichkeit gegen Thromboembolie
Barcelona (ots) – Edoxaban, ein oraler Faktor-Xa-Inhibitor, wird derzeit in der zulassungsrelevanten Phase-III-Studie ENGAGE AF-TIMI 48 (Effective aNticoaGulation with Factor xA Next GEneration in Atrial Fibrillation; Deutsch: Wirksame Gerinnungshemmung mit Faktor Xa-Präparaten der nächsten Generation bei Vorhofflimmern) als mögliche neue Behandlung zur Schlaganfallprävention bei Patienten mit Vorhofflimmern geprüft. In Europa leiden etwa 4,5 Millionen Menschen [...]
Edoxaban – next generation oral anticoagulant under investigation to help prevent stroke in patients with atrial fibrillation
Barcelona (ots) – New treatment could offer further option in addition to current standard of care in thromboembolic disease Edoxaban, an oral factor Xa inhibitor, is currently being investigated in the pivotal phase III study ENGAGE AF-TIMI 48 (Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation) as a potential new treatment for stroke [...]
WTC Business Day am 5. März 2009
(pressebox) Saarbrücken, 27.02.2009, Am Donnerstag, 5. März 2009, findet im Messegelände Metz (Metz Expo) der grenzüberschreitende WTC Business Day 2009 statt. Unter dem Motto "Networking in der Großregion Saarlorlux" bietet die Veranstaltung interessierten Unternehmen aus der verarbeitenden Industrie Gelegenheit, ihre Geschäftskontakte über die Grenzen hinweg auszubauen. Der WTC Business Day findet im Rahmen des 20jährigen [...]
